ARCHIMED, a French healthcare-focused private equity firm (PEF), plans to make a tender offer for Jeisys Medical, a global medical equipment maker listed on the KOSDAQ. The aim is a 72% stake (worth 724.4 billion won, $525.42 million), and if ARCHIMED is successful in the tender offer, Jeisys Medical is likely to delist voluntarily.

According to the investment banking (IB) sector, on June. 9., ARCHIMED will tender 55,724,838 common shares of Jeisys Medical between the 10th and 22nd of next month. The tender offer price is set at 13,000 won (about $9.43) per share, 20.8% more than the closing price of 10,760 won on the previous trading day, the 7th. The lead manager of the tender offer is NH Investment & Securities.

ARCHIMED intends to purchase all of the shares tendered if the total surpasses 18,013,879 shares (about 28.3%). If fewer shares are tendered, it will withdraw the tender offer entirely.

On June. 7., ARCHIMED inked a deal to purchase the full 23.2% share held by Kang Dong-hwan, Jeisys Medical’s founder and chairman of the board, as well as a portion of the 3.2% stake held by director Lee Myung-hoon.

Jeisys Medical, founded in 2004, specializes in aesthetic medical devices, specifically laser and ultrasound technologies for skin therapy. The company, listed in the KOSDAQ market in 2021 through a SPAC merger, reported 143 billion won (about $103.72 million) in sales and 36.3 billion won (about $26.33 million) in operating profit last year.